Bioxytran (OTCMKTS:BIXT – Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.02) EPS for the quarter, Zacks reports.
Bioxytran Stock Down 5.2%
BIXT stock opened at $0.03 on Friday. The firm has a 50 day moving average of $0.04 and a two-hundred day moving average of $0.05. Bioxytran has a 12 month low of $0.03 and a 12 month high of $0.17. The company has a market capitalization of $3.74 million, a price-to-earnings ratio of -1.65 and a beta of 1.95.
About Bioxytran
Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.
Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.
Read More
- Five stocks we like better than Bioxytran
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
- Japan’s Stealth Bull Market: How U.S. Investors Can Get Exposure
- 3 Stocks to Own If Gas Prices Keep Rising
Receive News & Ratings for Bioxytran Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioxytran and related companies with MarketBeat.com's FREE daily email newsletter.
